Avidity Biosciences, Inc.

NasdaqGM:RNA Stock Report

Market Cap: US$4.2b

Avidity Biosciences Management

Management criteria checks 2/4

Avidity Biosciences' CEO is Sarah Boyce, appointed in Oct 2019, has a tenure of 5.33 years. total yearly compensation is $11.14M, comprised of 5.7% salary and 94.3% bonuses, including company stock and options. directly owns 0.15% of the company’s shares, worth $6.43M. The average tenure of the management team and the board of directors is 2.1 years and 5.5 years respectively.

Key information

Sarah Boyce

Chief executive officer

US$11.1m

Total compensation

CEO salary percentage5.7%
CEO tenure5.3yrs
CEO ownership0.2%
Management average tenure2.1yrs
Board average tenure5.5yrs

Recent management updates

Recent updates

Companies Like Avidity Biosciences (NASDAQ:RNA) Are In A Position To Invest In Growth

Jan 01
Companies Like Avidity Biosciences (NASDAQ:RNA) Are In A Position To Invest In Growth

Avidity Biosciences: Intriguing Oligonucleotide Program To Monitor Over Longer Term

Oct 02

Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders

Aug 16

Avidity Biosciences, Inc. (NASDAQ:RNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$66.67

Aug 14
Avidity Biosciences, Inc. (NASDAQ:RNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$66.67

Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)

Aug 11
Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)

Avidity Biosciences: Muscular Dystrophy Breakthrough Propels To A 'Buy' Upgrade

Jun 14

Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline

May 19

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Mar 01
Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch

Feb 29

Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?

Nov 04
Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Apr 08
Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Nov 17
Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Avidity slips 20% as FDA places lead asset on partial clinical hold

Sep 27

We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth

Jul 29
We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth

Avidity stock rises amid Chardan starting coverage with Buy

Jul 20

Avidity, Dyn gain as Raymond James turns bullish on targeted oligonucleotides

Jul 12

We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely

Mar 26
We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely

CEO Compensation Analysis

How has Sarah Boyce's remuneration changed compared to Avidity Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$280m

Jun 30 2024n/an/a

-US$252m

Mar 31 2024n/an/a

-US$229m

Dec 31 2023US$11mUS$635k

-US$212m

Sep 30 2023n/an/a

-US$202m

Jun 30 2023n/an/a

-US$193m

Mar 31 2023n/an/a

-US$192m

Dec 31 2022US$5mUS$601k

-US$174m

Sep 30 2022n/an/a

-US$162m

Jun 30 2022n/an/a

-US$148m

Mar 31 2022n/an/a

-US$128m

Dec 31 2021US$6mUS$570k

-US$118m

Sep 30 2021n/an/a

-US$96m

Jun 30 2021n/an/a

-US$78m

Mar 31 2021n/an/a

-US$62m

Dec 31 2020US$823kUS$484k

-US$44m

Sep 30 2020n/an/a

-US$38m

Jun 30 2020n/an/a

-US$34m

Mar 31 2020n/an/a

-US$28m

Dec 31 2019US$4mUS$104k

-US$25m

Compensation vs Market: Sarah's total compensation ($USD11.14M) is above average for companies of similar size in the US market ($USD6.62M).

Compensation vs Earnings: Sarah's compensation has increased whilst the company is unprofitable.

CEO

Sarah Boyce (52 yo)

5.3yrs

Tenure

US$11,139,719

Compensation

Ms. Sarah Boyce is Director of Abcuro, Inc. from July 2024. She serves as Independent Director of Contineum Therapeutics, Inc Since June 2024. She has been President, Chief Executive Officer and Director a...

Leadership Team

NamePositionTenureCompensationOwnership
Troy Wilson
Co-Founder & Independent Chairman12.3yrsUS$260.31k0.064%
$ 2.7m
Sarah Boyce
President5.3yrsUS$11.14m0.15%
$ 6.4m
W. Michael Flanagan
Chief Scientific Officer2yrsUS$4.89m0.077%
$ 3.2m
Teresa McCarthy
Chief Human Resources Officer4.5yrsUS$3.73m0.088%
$ 3.7m
Eric Mosbrooker
Chief Commercial Officer1.1yrsUS$235.31k0.030%
$ 1.3m
Mark Davis
Scientific Founder13.1yrsno datano data
Frank McCormick
Scientific Founder & Member of Scientific Advisory Board13.1yrsno datano data
Charles Calderaro
Chief Technical Officerless than a yearno datano data
John Moriarty
Chief Legal Officer & Corporate Secretaryless than a yearno datano data
Kathleen Gallagher
Chief Program Officer2.1yrsno data0.016%
$ 679.0k
Steven Hughes
Chief Medical Officer3yrsno data0.022%
$ 909.4k
Kat Lange
Senior VP & Chief Business Officerless than a yearno datano data

2.1yrs

Average Tenure

56yo

Average Age

Experienced Management: RNA's management team is considered experienced (2.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Troy Wilson
Co-Founder & Independent Chairman12.3yrsUS$260.31k0.064%
$ 2.7m
Sarah Boyce
President5.3yrsUS$11.14m0.15%
$ 6.4m
Mark Davis
Scientific Founderno datano datano data
Frank McCormick
Scientific Founder & Member of Scientific Advisory Boardno datano datano data
Arthur Levin
Directorno dataUS$3.03m0.13%
$ 5.5m
Carsten Boess
Independent Director4.8yrsUS$245.31k0%
$ 0
Richard Heyman
Member of Scientific Advisory Boardno datano datano data
Edward Kaye
Independent Director5.5yrsUS$244.31k0%
$ 0
Eran Nadav
Observerno datano datano data
Christopher Kirk
Member of Scientific Advisory Boardno datano datano data
Noreen Henig
Independent Director5.5yrsUS$245.81k0%
$ 0
Ryan Corcoran
Member of Scientific Advisory Boardno datano datano data

5.5yrs

Average Tenure

58.5yo

Average Age

Experienced Board: RNA's board of directors are considered experienced (5.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 01:07
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Avidity Biosciences, Inc. is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
Tazeen AhmadBofA Global Research
Eric SchmidtCantor Fitzgerald & Co.